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size range can be achieved by the use of 
higher molecular weight (MW) biode-
gradable carriers or the self-assembly of 
individual unimeric species to yield larger 
nanostructures. Acquired knowledge in the 
design of drug delivery systems (DDSs) 
is raising awareness about the need for 
fully biodegradable and biocompatible car-
riers.[5] In this framework, well-defined 
polypeptides with advanced engineered 
complexity and structural versatility arise 
as perfect candidates with proven thera-
peutic potential and clinical translation.[6] 
The intrinsic architectural, conformational, 
and multifunctional properties of branched 
polypeptides, inaccessible to linear poly-
mers, together with their tunable and fea-
ture accelerated manufacture compared 
to dendrimers, make their application as 
DDS a potentially exciting proposition.[7]
The rising potential of polymer self-assembled DDS is nowa-
days only limited to mastering the molecular interactions such 
as hydrophobic effect, host–guest or electrostatic interactions, 
among others.[8] While seemingly counterintuitive, charge-like 
macromolecule aggregation has been described from a theoret-
ical standpoint[9] and represents a ubiquitous phenomenon in 
biology, involved, for example, in virus capsid and microtubule 
(F-actin) self-assembly, DNA condensation, and chromosome 
motion.[10] The successful integration of mean field, counterion 
condensation, and Flory theories for polyelectrolyte solution 
has shed light on this self-assembly phenomenon.[11–13] Experi-
mental evidence for charge-like attraction arises from the obser-
vation of two diffusional regimes, the “fast” and “slow” modes 
observed from dynamic light-scattering (DLS) experiments.[13,14] 
Particularly relevant for the present work is the “slow” mode, 
also referred as “extraordinary” behavior, where polyions expe-
rience attraction at certain concentrations and low salt content 
to yield aggregated species. Experimental reports of such aggre-
gation mechanism have mainly been reported from scattering 
techniques and approached from a theoretical standpoint. This 
may be due to the transient, disordered, and reversible nature 
of these soft materials, which not only makes sample manipula-
tion and observation difficult, but also hinders their applicability.
In our attempts to develop improved nanosized DDSs based 
on star-shaped polyglutamates, we identified this unexpected 
charge-like attraction mechanism of self-assembly. In this 
study, we used a wide array of techniques to provide consistent 
The rational design of nanomedicines is a challenging task given the com-
plex architectures required for the construction of nanosized carriers with 
embedded therapeutic properties and the complex interface of these mate-
rials with the biological environment. Herein, an unexpected charge-like 
attraction mechanism of self-assembly for star-shaped polyglutamates in 
nonsalty aqueous solutions is identified, which matches the ubiquitous 
“ordinary–extraordinary” phenomenon previously described by physicists. For 
the first time, a bottom-up methodology for the stabilization of these nano-
sized soft-assembled star-shaped polyglutamates is also described, enabling 
the translation of theoretical research into nanomaterials with applicability 
within the drug-delivery field. Covalent capture of these labile assemblies 
provides access to unprecedented architectures to be used as nanocarriers. 
The enhanced in vitro and in vivo properties of these novel nanoconstructs 
as drug-delivery systems highlight the potential of this approach for tumor-
localized as well as lymphotropic delivery.
Nanocarriers
Nanomedicine and nanotechnology have emerged to address 
unmet medical needs in cancer treatment[1] and recently 
expanded into other areas including neurological disorders or 
infectious diseases.[2] The translation of nanoproducts to routine 
clinical use has demonstrated their potential.[3] A nanocarrier 
size range between 20 and 100 nm is optimal to enhance blood 
circulation times and promotes an effective passive targeting by 
the “enhanced permeability and retention (EPR) effect.”[4] This 
© 2017 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, 
Weinheim. This is an open access article under the terms of the Creative 
Commons Attribution-NonCommercial License, which permits use, dis-
tribution and reproduction in any medium, provided the original work is 
properly cited and is not used for commercial purposes.
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experimental evidence for the “extraordinary” behavior. For the 
first time, we show how a bottom-up methodology reliant on the 
molecular design and covalent stabilization of highly dynamic 
coassemblies via “extraordinary” behavior allows the construc-
tion of otherwise inaccessible nanostructures of 30–100 nm in 
radius, a size ideal to promote long-blood circulation times and 
enhanced therapeutic effect, particularly in cancer treatments.
We synthesized a family of well-defined 1,3,5-benzenetricarb-
oxamide (BTA)-centered star-shaped polyglutamates (sodium 
salts) with control on target degree of polymerization, narrow 
MW distributions, and arm length symmetry in a reproduc-
ible and scalable manner (Figure 1a and synthetic details in 
the Supporting Information).[15] Synthesized compounds dif-
fered structurally on the polyglutamate degree of polymeriza-
tion with ≈25 or 50 glutamic units per arm and a BTA core 
motif bearing different spacers (Figure 1a, compounds 1a–e). 
To gain a deep understanding of these systems and to acknowl-
edge industrial and clinical translation concerns, we performed 
a detailed characterization of the compound 1 family. DLS 
measurements in deionized aqueous solutions for compound 
1a revealed nanosized objects with a concentration dependent 
hydrodynamic radius (Rh) in the range of 4–200 nm (Figure 1b, 
left). The smaller size must be attributed to star-polyglutamate 
unimers[15,16] whereas the increase in Rh to 40 and 200 nm 
observed at 1 and 10 mg mL−1, respectively, suggested an unex-
pected self-association of unimers. We also observed a large 
critical aggregation concentration (CAC) compared to amphi-
philic block copolymers, as derived from the scattered inten-
sity versus concentration measurements (CAC ≈ 0.5 mg mL−1, 
Figure 1b, middle).[17] Below the CAC, compound 1a was pre-
sent as an anionic unimeric specie with a negative z-potential 
from −25 to −35 mV. Above the CAC, we recorded a sharp 
increase in the scattered light and the negative z-potential. Of 
note, the linear counterpart displayed no evidence of this self-
assembly behavior at the concentrations studied (Figure S23, 
Supporting Information). Tested derivatives from compound 
1a presented CAC values in the same range, independently of 
the core nature or arm length (Figure S23, Supporting Infor-
mation). Transmission electron microscopy (TEM) images 
(also see Figure S24 in the Supporting Information) confirmed 
the existence of nanosized spherical aggregates of 50–100 
and 200–300 nm in size for 1a at 1 mg mL−1 (Figure 1c, left) 
and 10 mg mL−1 (Figure 1c, right), respectively, in agreement 
with DLS data. A closer inspection of morphology evidenced 
low material density and amorphous nature, as confirmed 
by the flat X-ray powder diffraction pattern registered for 
freeze-dried samples of 1a in H2O (Figure S26, Supporting 
Information).
Although BTA is a widely used self-assembling motif that 
can induce defined molecular ordering within different supra-
molecular materials,[18] it requires hydrophobic groups to pro-
mote self-assembly in aqueous media.[19] At the molecular level, 
all attempts to prove the role of BTA in the self-assembly pro-
cess, performed by fluorescence spectroscopy employing hydro-
phobic probes (pyrene and Nile Red, Figure S27 and S28, Sup-
porting Information) or small-angle neutron scattering (SANS) 
contrast experiments of compound 3 (Figure S32, Supporting 
Information), failed to provide evidence of enriched BTA stack 
domains.[20] Our findings suggested a poor molecular order 
in the assemblies and the null participation of the BTA motif 
in driving the self-association process, as one would expect, 
since it only represents a small molar fraction of our system. 
However, circular dichroism (CD) allowed the identification of 
a characteristic feature for compound 1a, with a recurrent red-
shift of the negative band at 200 nm above the CAC (Figure 1d 
and Figure S34, Supporting Information). This small shift was 
most likely generated due to partial constraint or orientation of 
the arms within the assemblies rather than small coil to helix 
transition of polyglutamate secondary structure upon partial 
protonation of carboxylic acids, which was negligible at the 
working pH (Figure S42 and Table S10, Supporting Informa-
tion). We note that size values did not experience significant 
changes in a physiologically relevant pH range (from pH 5 to 8) 
(see Figure S35 in the Supporting Information). In order to 
disprove the existence of intra- or intermolecular H-bonding 
along the polypeptidic backbone, we performed DLS titration 
experiments using common denaturants. Figure 1b (right) 
demonstrated that while assembly size did not significantly 
change following the addition of the nonionic denaturant urea, 
we observed rapid salt-mediated disassembly upon addition of 
ionic guanidinium chloride at low concentrations (10 × 10−3 M) 
or salts of opposite nature within the Hofmeister series 
(Figure S36, Supporting Information).[21] This experiment 
was key in elucidating the driving forces ruling the polyion 
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Figure 1. Self-assembly of star-shaped poly(L-glutamates) in aqueous media. a) BTA centered star-shaped poly(L-glutamates) (compounds 1a–c) have 
been synthesized through ring opening polymerization of N-carboxyanhydride methodology (see the Supporting Information for synthetic and charac-
terization details). b) Dynamic light scattering analysis of compound 1a in ddH2O demonstrates the dependence of the aggregation behavior on con-
centration (left panel) with a critical aggregation concentration estimated at around 0.5 mg mL−1 and a sharp decrease in z-potential value recorded 
(center panel, also see Figure S23 in the Supporting Information). Variable ionic strength experiments employing denaturating guanidinium chloride 
(GuCl) demonstrates assembly disruption to unimers at low salt concentrations (10 × 10−3 M) for compound 1a (2 mg mL−1) not observed when a 
nonionic denaturating analog such as urea was employed (right panel, also see Figure S35 and S36 in the Supporting Information). c) TEM images 
show the presence of 50–100 nm spherical particles in water at 1 mg mL−1 (left panel scale bar 200 nm, inset scale bar 50 nm) and up to 200–300 nm 
size at increased concentration of 10 mg mL−1 (right panel scale bar 200 nm, inset scale bar 50 nm), in good agreement with concentration depend-
ence size observed by DLS (see Figure S24 in the Supporting Information for more TEM images). d) Circular dichroism shows a small redshift in the 
negative band of the random coil conformation of 1a and above the CAC value (also see Figure S34 in the Supporting Information). e) Small angle 
neutron scattering (SANS) data analysis for compound 1a (see full data in Figure S29 in the Supporting Information). Table displays the best-fit for 
the Gaussian coil for a Dozier star polymer model for compounds 1a–1e. f) Cryo-TEM images of compound 1a in aqueous solution (2 mg mL−1) 
suggests a spherical assembly geometry with sizes ranging from ≈50 to 150 nm in diameter (scale bars: left and right panels are 100 nm, right inset 
is 50 nm, dense black spheres are 6 nm nanogold particles). g) 3D reconstructed tomograms from the same sample (scale bar: 50 nm, additional 
3D reconstructions displayed in Figure S25 in the Supporting Information). h) The proposed aggregation equilibrium model based on all the data 
registered within the present study.
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self-assembly observed in our system and suggested ionic inter-
actions as the main actors.
Cryo-TEM imaging for compound 1a confirmed the exist-
ence of spherical objects of 30–100 nm in radius (Figure 1f). 
Visualization of isolated objects permitted the acquisition of 
tomographic series and 3D reconstruction of the selected nano-
particle (Figure 1g). We noted that the low contrast appear-
ance and the homogeneous low electron density along the 
aggregate’s structure discounted the existence of a defined 
core–shell. Furthermore, the irregular surface and globular 
geometry deviated from ideal spheres (additional 3D tomogram 
in Figure S25 in the Supporting Information), probably due to 
the dynamic and loose nature of the assemblies. Analysis of 
data acquired from SANS experiments for compounds 1a–e in 
D2O (Figure 1e) demonstrated a best fit for the “Gaussian coil 
for a Dozier star polymer” model.[22] Fitted parameters revealed 
a radius of gyration (Rg) of 80–100 nm matching the data 
obtained for compound 1a via DLS and electron microscopy 
and again suggested the self-association of unimeric species. 
In the absence of interparticle interactions (where the interpar-
ticle structure factor value is S(Q) = 1, see Figure S29 in the 
Supporting Information for more details), the Flory component 
value variation (ν) was found to be small (close to ⅓), indicating 
a relatively poor solvent and suggested that the studied poly-
mers were in a collapsed conformation (dense stars). Further-
more, packing close to the core was influenced by the packing 
efficiency of the substituents (i.e., the polymer packed around 
a larger overall excluded volume for ethyl than hexyl). Moving 
toward the outer layers, it seemed that the arms tended to reor-
ganize themselves around a fixed core; hence, the core is simply 
more “wrapped” as MW increases, allowing the Rg to remain 
relatively unchanged within the assemblies. The ξ parameter 
provides an indication of how the polymer swelling changes 
upon the distance from the core. The ξ parameters were clearly 
dependent on the substituent used, and varied in the order: 
ethyl (1a,b) > 3,6-dioxa-8-octane (DOOA) (1c,d) > hexyl (1d). 
When combined with the Flory parameter, this provided a con-
sistent picture of how the conformation varies with MW: for 
larger Rg values the larger core area to cover results in more 
swollen outer layers and higher ξ values. Rg values varied in the 
same order as ξ: ethyl > DOOA > hexyl substituents in the BTA 
core; but, surprisingly, there was no dependence on MW (also 
see Figure 1e and Figure S29 in the Supporting Information), a 
key concept for the 3D shape elucidation (Figure 1h).
In summary, aggregation of star-shaped polyglutamates 
occurred in a nonsalty aqueous environment following 
polyion concentration dependence with a defined and large 
CAC together with a fast disassembly upon increasing ionic 
strength. Lack of spectroscopic features points toward a rather 
amorphous material with only a recurring characteristic sig-
nature involving partial constrain of polyglutamate chains. 
More importantly, evidence suggested that the self-assembly 
phenomena proceeded via ionic interactions. These features 
are characteristic fingerprints of the ubiquitous “ordinary to 
extraordinary” behavior transition in the dynamics of charged 
macromolecules in aqueous solutions.[11–13] Although the 
rational has been controversial for years, there is now a con-
sensus to rationalize the self-assembly of charge-like polyions 
based on counterion condensation theory. This theory states 
that electrostatic potential becomes attractive as the modeled 
lines of charges approach within the Debye length and the con-
densed counterions are merged in a shared cloud.[12] Recently, 
Muthukumar has approached this phenomena collecting 
reported data over the last decades.[13] Very interestingly, this 
model predicts a threshold value of a combination of polyion 
(CAC) and electrolyte concentration (millimolar range) for the 
transition to the “extraordinary” behavior. Under these condi-
tions, the observed “slow” diffusional mode results from the 
presence of polyion clusters due to the formation of transient 
dipoles arising from adsorbed counterions on polyion back-
bone that can act as physical cross-linking points. This rational 
is in agreement with the observed behavior on compounds 
1a–e, which displayed a CAC threshold and electrolyte con-
centration for the self-assembly within the range predicted by 
Muthukumar. The redshift observed in CD analysis can also be 
linked to the formation of physical cross-linking dipoles. The 
fact that we did not observe this behavior for the linear counter-
parts within the concentrations studied points to the influence 
of branching, topology, and charge density of compounds 1 that 
would promote the formation of these cross-linking dipoles.
When compared to reported self-assembled DDS, the archi-
tectures generated via “extraordinary” behavior inherently 
display differential physicochemical features that mediate 
interactions with biological systems, including size, surface 
hydrophilicity, charge, lack of internal structure, and enhanced 
deformability.[23] To assess the biological performance of our 
new architectures, we aimed to covalently capture our assem-
blies, as the loose nature of uncaptured assemblies will result in 
rapid disaggregation in biological media due to increased ionic 
strength (≈130 × 10−3 M) and large dilution rates.[24] Toward this 
aim, we studied the dynamics, reversibility, and coassembly 
properties of these systems via stochastic optical reconstruc-
tion micro scopy (STORM), Förster resonance energy transfer 
(FRET),[25] and nuclear magnetic resonance (NMR) techniques.
We modified compound 1a on side chains following 
well-established methodologies[26] with Cy3 (compound 2c) 
and Cy5 (compound 2d), a FRET pair suitable for STORM 
microscopy[25,27] (Figure 2a and Figure S15–S18 and Table S3 
(Supporting Information)). We obtained a concentration-
dependent FRET signal when compounds 2c and 2d were coas-
sembled, indicating that the two dyes (and therefore the two 
unimers) were in close proximity within common aggregates 
(Figure 2b). A key feature of supramolecular aggregates is their 
dynamic nature, i.e., their ability to continuously assemble and 
disassemble exchanging monomers. We studied monomer 
exchange kinetics between preassembled compounds 2c and 
2d by FRET. Immediately after mixing, a plateau in the signal 
ratio (and therefore, an equilibrium state) occurred before the 
first observation time, highlighting the very dynamic nature of 
our systems.[27] To confirm these indirect spectroscopic observa-
tions, we also performed super-resolution STORM experiments 
for the 2c and 2d compounds. Figure 2d demonstrates that all 
aggregates were single-colored in single component samples 
(Figure 2d, left); however, both unimers were present within 
the same nanoassemblies after 2 min of mixing, confirming the 
rapid monomer exchange observed in FRET studies. Notably, 
coassembled aggregates of 100–200 nm coexisted with smaller 
single colored structures, likely to be unimers or low-order 
Adv. Mater. 2017, 1702888
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oligomers (Figure 2e). Overall, these experiments proved the 
highly dynamic and reversible nature of the assemblies, evi-
dencing the possibility to build coassembled multifunctional 
DDS and also stressing the need of stabilization for application 
in biological environments.
To this end, we modified compound 1a at the side chain 
with different degrees of functionalization of azides (com-
pound 2a) or alkynes (compound 2b) pursuing a nonreversible 
covalent stabilization of the assemblies through copper- 
catalyzed alkyne/azide cycloaddition (CuAAC) (Figure 2a 
and Figure S12–S14 and Table S2 (Supporting Information)). 
Although functionalization did not significantly alter the 
assemblies (up to a 30% molar glutamic acid units substi-
tution, as evidenced by DLS, Figure S37–S40 and Table S8 
and S9, Supporting Information), the modification rates for 
the covalent capture were established as 5% and 10% for 
compounds 2a and 2b, respectively, displaying sizes similar to 
model compound 1a (Figure S30 and S31 and Table S6 and S7, 
Supporting Information).
We next confirmed the coassembly of compounds 2a and 
2b by pulsed-field-gradient spin-echo (PFGSE) NMR experi-
ments[28] and determined diffusion coefficients of com-
pounds 1a, 2a, and 2b in D2O above (2 mg mL
−1) and below 
(0.1 mg mL−1) CAC values (Figure 3). Diffusion coefficients in 
the unimeric state (3 × 10−11 m2 s−1) were found to be one order 
of magnitude higher than those for aggregated nanoassemblies 
(4.5 × 10−12 m2 s−1), indicating Rh values of 6 and 44 nm for uni-
mers and assemblies, respectively, in agreement with DLS data 
(Figure 3b and Figure S43–S45 (Supporting Information)). We 
doped a sample containing preassembled compound 2b with 
2a at a concentration below its CAC. As shown in Figure 3b, 
the incorporation of 2a unimers within 2b nanoassemblies 
Adv. Mater. 2017, 1702888
Figure 2. Dynamics and reversibility of the self-assembled star-shaped polyglutamates. a) Star-shaped polyglutamates were fluorescently labeled 
through postpolymerization modification procedures with Cy3 and Cy5, respectively (see synthetic methods in the Supporting Information). b) FRET 
ratio reduction upon dilution within nonlabeled compound 1a (horizontal axis) of fluorescently labeled derivatives (compounds 2d and 2c) demon-
strates that assembled structures contain both dyes and FRET transfer occurs. c) Mixing of compound 2c structures (90% 1a + 10% 2c) and com-
pound 2d structures (90% 1a + 10% 2d) at a concentration of 2.5 mg mL−1 to study their dynamic behavior in time shows small change in FRET ratio. 
d) STORM images of St–Poly(L-glutamate)(PGA)–Cy3, St–PGA–Cy5, and of the mixture of both structures (2.5 mg mL−1) after 1–2 min of incubation 
demonstrate a fast dynamic event to the equilibrium state as evidenced by the co-localization of 2c and 2d labeled compounds within common aggre-
gates (right panel, dashed lines scale bar 1 µm). e) Schematic illustration of component exchange in the assemblies observed by STORM, confirming 
the highly dynamic and reversible nature of the self-assembled nanostructures.
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was evidenced by the Df value obtained for 2a corresponding 
to self-assembled 2b (≈5 × 10−12 m2 s−1). We obtained direct 
proof for spatial proximity through nuclear Overhauser effect 
spectroscopy (NOESY) NMR experiments where we identified 
a clear correlation between azide and alkyne motifs (2a and 2b, 
respectively) (Figure S46, Supporting Information).
Our results point to the feasibility of a covalent capture 
strategy using CuAAC (Scheme S4 and Figure S19, Supporting 
Information) and we next monitored assembly stability during 
coupling conditions (ionic strength = 2 × 10−3 M) of a 1:1 mixture 
ratio of compounds 2a and 2b via DLS (Figure 3d, left). Results 
showed that after CuAAC reaction, the self-assembled polyglu-
tamates were stable following dilution (with a slight compaction 
to Rh of 30–40 nm also evidenced by cryo-TEM image shown in 
Figure 3c) or an increased presence of ionic species. This sta-
bility differed from the results found for a physical mixture as 
revealed by DLS (Figure 3d) and SANS experiments (Figure S31 
and Table S7, Supporting Information). With regard to indus-
trial and clinical concerns, we found the assembly mechanism 
and covalent capture strategy to be highly robust and reproduc-
ible (Figure S37–S41 and Table S8 and S9, Supporting Informa-
tion). The covalent capture of dynamic assemblies is a highly 
attractive proposition, as they have the potential to be applied 
in novel DDS strategies containing unique features that could 
yield advantageous biological consequences.
We labeled compound 4 with fluorescence dyes to monitor 
in vitro and in vivo performance (Figure 4), yielding com-
pounds 5a (bearing Oregon Green, for live-cell imaging, see 
the Supporting Information) and 5b (with Cy5.5, for in vivo 
imaging). Importantly, surface modification of compound 
4 did not induce structural changes in the parental structure 
(Figure 4a,b and Figure S34 and S38 and Table S8 and S9 
Adv. Mater. 2017, 1702888
Figure 3. Covalent capture strategy toward stable and long circulating delivery systems. a) Coassembly of prefunctionalized and complementary 
compounds 2a and 2b (1) and covalent capture of the coassembled components through azide–alkyne click-chemistry to yield covalently captured 
compound 4 (2). b) PGFSE-NMR experiments monitored changes in the diffusion coefficient of unimeric compound 2a (0.1 mg mL−1) in the presence 
of assembled compound 2b (2 mg mL−1) (see Figure S43–S45 in the Supporting Information). Analysis shows a reduction in the diffusion coefficient 
by one order of magnitude of unimeric compound 2a and indicates the incorporation of these unimers within the assembled compound 2b nanostruc-
tures (table). This provides indirect evidence for the coassembly of these complementary components. c) Cryo-TEM image visualization of covalently 
captured nanosized compound 4 assemblies (2 mg mL−1, scale bar 50 nm) (also see Figure S25 in the Supporting Information). d) DLS permitted the 
assessment of assemblies stability along the CuAAC reaction (left panel) and the efficiency of the covalent capture strategy to hinder the reversibility 
of the system upon dilution (center panel) or increased ionic strength (right panel). Also see, Figure S35 and S36 in the Supporting Information.
www.advmat.dewww.advancedsciencenews.com
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Figure 4. Biological validation of the covalently captured nanostructures as drug delivery systems. a) Schematic representation of the surface modification of 
compound 4 with fluorescence dyes. b) Nanoparticle Tracking Analysis (NTA) in ddH2O shows particle distribution of compound 5b in agreement with DLS 
and Cryo-TEM. c) SHSY5Y cell viability by MTS assay in response to compound 4 (72 h) demonstrated lack of toxicity (n > 3, mean ± SEM). d) Cell-associated 
www.advmat.dewww.advancedsciencenews.com
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(Supporting Information)). Cell viability assays using SHSY5Y 
neuroblastoma cells as model cancer cell line and human 
fibroblasts derived from new-born foreskin as a normal cell 
model revealed absence of cell toxicity up to the concentrations 
tested, (see Figure S48 in the Supporting Information), sug-
gesting the feasibility of the CuAAC strategy after proper Cu 
removal (Figure 4c). A lack of toxic side effects was also dem-
onstrated via histological analysis of tissue slices of key organs 
extracted from 5b-treated animals at 24 and 72 h postinjection 
(Figure S53, Supporting Information).
As expected for macromolecular systems of such origin,[29] 
an energy-dependent uptake was observed (Figure 4d) with a 
clear co-localization of compound 5a with LysoTracker Red indi-
cating the suitability of these nanocarriers for lysosomotropic 
drug delivery[30] (Figure 4e). Importantly, in neuroblastoma 
cells, a significantly enhanced in vitro cell internalization rate 
for compound 5a when compared with linear-polyglutamate 
and star unimer (1a), was demonstrated by flow cytometry 
and live-cell confocal microscopy, probably due to the larger 
size and greater negative z-potential (Figure S49 and S50, 
Supporting Information).[31] In vivo biodistribution of 5b in 
healthy mice revealed renal excretion profiles, as observed for 
other polyglutamates.[15] Larger accumulation in all organs 
generally occurred for 5b and, importantly, we also observed 
significantly greater terminal and accumulation half-life for 
5b (t1/2 beta 115.6 h and t1/2 alpha 1.1 h) when compared to 
the linear (0.6 and 0.10 h) or star unimer (1a) counterparts 
(12 and 0.15 h), respectively (Figure S51 and S52 and Table S11, 
Supporting Information).[15] Increased half-life may enhance 
passive targeting by the EPR effect when used in well-vascular-
ized solid tumors or inflamed areas[4] (Figure 4f,g).
Remarkably, we observed a clear accumulation of compound 
5b in immune system-related organs including the spleen and 
lymph nodes (axillary (ALN) and cervical (CLN)) (Figure 4h, 
p < 0.001), highlighting the great potential of our stabilized self-
assemblies as carriers to target lymph node metastasis, cancer 
immunotherapy, or immune system-related approaches, such 
as vaccination after the adequate conjugation of antigens or 
adjuvants.[32,33] The preferential internalization by macrophages 
and other immune-system related cells of the polyglutamate-
based nanocarriers as already seen clinically[34] together with 
5b intrinsic physicochemical properties may contribute to such 
behavior. Indeed, the inherent structural and morphological fea-
tures of these soft materials, such as their size range (≈100 nm), 
highly negative z-potential values, and/or hydrophilic surfaces, 
represent key features for lymph node targeting.[32,35,36] Our 
findings are of special interest given that we obtained up to 40% 
injected dose per gram tissue 5b accumulation in the lymph 
nodes after intravenous administration. Although a direct com-
parison would not be rigorous given the large heterogeneity in 
the animal models and techniques employed for quantification 
in literature, this accumulation value stands among the max-
imum reported values in literature so far, and could even be 
enhanced by employing subcutaneously administration.[35,37] 
These data demonstrate the applicability of our self-assembled 
polyglutamates as lymphotropic delivery vehicles, opening up a 
vast range of therapeutic approaches.
Within this study, we have provided a simple yet efficient 
bottom-up approach for the design of long circulating nanocar-
riers, taking advantage, for the first time, of the “extraordinary” 
behavior identified for star-shaped polyglutamates in nonsalty 
aqueous solutions. In our attempts to construct advanced 
nanosized carriers based on star-shaped polyglutamates, we 
identified a charge-like self-assembly phenomena for electrostat-
ically repulsive macromolecules that may represent a paradigm 
shift for conventional nanocarrier design. A thorough study 
employing a wide battery of instrumental techniques allowed us 
to rationalize these observations under the so-called “ordinary 
to extraordinary” transition behavior. We noted that under low 
ionic strength (<10 × 10−3 M), these charged macro molecules 
experience an unexpected self-assembly process, yielding 
spherical objects in the range of 30–100 nm in radius, a highly 
negative z-potential with a highly dynamic equilibrium, and a 
rapid disassembly upon an effective charge screening. This 
self-assembly mechanism was found to be driven by ionic inter-
actions following a recently reported model, where the adsorbed 
counterions are shared in a merged cloud creating transient 
dipoles in the polyanionic backbone that can act as cross-linking 
points. We constructed these biodegradable and biocompatible 
self-assembled cross-linked star-shaped poly glutamates using a 
reproducible and scalable bottom-up methodology followed by 
a covalent stabilization. This strategy enabled in vitro and in 
vivo evaluation, revealing a lack of toxicity, an enhanced in vitro 
cell internalization rate, and significantly greater terminal and 
accumulation half-life in vivo. These results allow us to envisage 
these systems as promising nanocarriers for therapeutic or 
diagnostic applications, especially in anticancer treatments. 
Additionally, further studies to identify the mechanism for the 
significant accumulation found in the lymph nodes will open 
up a wide range of opportunities for the currently unsuccessful 
clinical approaches to target lymph node metastasis, imaging of 
sentinel lymph nodes, and cancer immunotherapy.
Experimental Section
Synthesis of Star-Shaped Poly(L-glutamates): Detailed synthetic 
methodologies and full characterization of the initiators, monomers, 
polymerizations, deprotection steps, postpolymerization modifications, 
and covalent capture strategies are fully described in the Section 
“Synthetic Procedures” in the Supporting information.
DLS: DLS measurements were performed using a Malvern 
ZetasizerNanoZS instrument, equipped with a 532 nm laser at a fixed 
scattering angle of 173°. Solutions were sonicated for 10 min and 
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fluorescence (CAF) over time of the energy-dependent uptake (experiment at 37–4 °C to exclude binding) shows a significant increase for compound 5a (n > 3, 
mean ± SEM). e) Confocal image of compound 5a uptake at 2 h post-treatment in SHSY5Y cells following a pulse–chase experiment (Blue-Hoechst 33342 for 
nuclei; Green-Oregon-green for compound 5a; Red-LysoTracker Red). Colocalization with LysoTracker marker was observed (yellow). f) In vivo biodistribution 
after intravenous injection of compound 5b shows renal excretion profiles with accumulation in lymph nodes. Data expressed as normalized % injected dose 
(ID) per gram of tissue (n > 5, mean ± SEM). g) Pharmacokinetic parameters obtained from compound 5b plasmatic profiles. h) In vivo biodistribution of 
compound 5b toward 1a and linear PGA at 1 and 4 h postinjection confirms the clear significantly higher accumulation of 5b in spleen and lymph nodes 
(axillary, ALN and cervical, CLN). Data expressed as normalized % injected dose (ID) per gram of tissue (n > 5, mean ± standard error of the mean (SEM)).
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allowed to age for the required time, filtered through a 0.45 µm cellulose 
membrane filter, and measured. Size distribution was measured (radius, 
nm) for each polymer in triplicate with n > 3 measurements.
For size measurements, polymer solutions were prepared under 
different conditions (double-deionized water, ddH2O, phosphate 
buffers, or salt containing solutions at different concentrations 
and temperatures). Automatic optimization of beam focusing and 
attenuation was applied for each sample. CAC was determined using a 
previously described method.[17]
TEM Images: TEM images were recorded using a JEOL 2100 
transmission electron microscope. Samples of polyglutamates were 
applied directly onto carbon film on 200 mesh copper grids. Excess 
of sample was carefully removed by capillarity, and the grids were 
immediately stained with one drop of 0.1% phosphotungstic acid for 
30 s. Excess stain was removed by capillary action.
Cryo-TEM Tomography: In order to achieve the 3D characterization 
of star-shaped self-assembled systems, a series of different electron 
tomograms was obtained. The sample was incubated in Quantifoil 
R3.5/1 holey carbon copper grids and vitrified using standard procedures 
with a Vitrobot (FEI). The samples included 10 nm gold nanoparticles 
(as fiducial markers) used in alignment process. Vitrified grids were 
transferred into a 914 high tilt cryo transfer tomography holder (Gatan 
Inc.) and analyzed on a JEM-2200FS/CR (JEOL, Ltd.) field emission gun 
electron microscope, operating at 200 kV at nitrogen liquid temperature. 
Single-axis tomographic tilt series were collected under low-dose 
conditions on a 4k × 4k UltraScan 4000 charged-coupled device (CCD) 
camera (Gatan Inc.), over a tilt range of ±64° with 2° increments and 
at underfocus values ranging from 5 to 8 mm, using the semiautomatic 
data acquisition software SerialEM. Different tilt series at a nominal 
magnification of 30 000, producing a final pixel size of 0.71 nm, were 
collected with SerialEM in low-dose mode. The in-column Omega energy 
filter helped to record images with improved signal-to-noise ratio by zero-
loss filtering with an energy slit width of 30 eV centered at the zero-loss 
peak. The total dose used for a tilt series was 90–100 electrons A°−2.[38]
Tomographic Reconstruction: For alignment and 3D reconstruction of 
the tilted series, IMOD software was used. 10 nm gold particles were 
used as fiducial markers during alignment, and 3D reconstruction was 
carried out by weight back-projection. No contrast transfer function 
(CTF) correction was applied, thus limiting the reconstructions to the 
first zero of the CTF.[39]
SANS: SANS experiments were performed using the D11 
diffractometer at the Institute Laue–Langevin (ILL, Grenoble), and 
diffractometers SANS2d and LOQ at the ISIS Spallation Neutron Source 
(Didcot, UK). All solutions were prepared in D2O at concentrations of 
1–0.01 wt% and were placed in 2 mm path length, UV-spectrophotometer 
grade, quartz cuvettes (Hellma UK) and mounted in aluminum holders 
on top of an enclosed, computer-controlled, sample chamber. Sample 
volumes were ≈0.6 cm3. Temperature control was achieved using 
a thermostated circulating bath pumping fluid through the base of 
the sample chamber, achieving a temperature stability of ±2 °C. Data 
were collected and corrected for the scattering and transmission of the 
solvent and cell and were placed on an absolute intensity scale with 
reference to a flat scatterer. Scattering data are expressed in terms of 
the scattering vector Q which is given by Q = 4npi/λsin(θ/2) in which 
n is the refractive index for neutrons (n ≈ 1), λ is the wavelength, and θ 
is the scattering angle. Data were corrected for transmission intensity, 
electronic background and normalized against a flat scatter according to 
standard procedures for the instrument. The obtained scattering profiles 
I(Q) versus Q were analyzed according to I(Q) ∝ ΦVpP(Q)S(Q) + Binc 
where Φ is the volume fraction and Vp the particle volume. Binc is the 
incoherent scattering, generally dominated by the protons present in 
the sample, which usually depends on the concentration of polymer. The 
FISH modeling suite was used for the analysis.[40] FISH incorporates 
parameterized form factors, P(Q) and structure factors, S(Q), to 
describe the dimensions of the scattering particle and interparticle 
interaction.
FRET: Unimer stock solutions of compounds 1a, 2d, and 2c at a 
concentration of 0.25 mg mL−1 were prepared. For dilution experiments, 
the stock samples were mixed in a ratio of 80/10/10 1a/2d/2c; while 
for dynamic experiments, stock solutions were mixed to obtain 10% 
2c or 2d/1a. Samples were lyophilized, suspended in ddH2O water at 
a concentration of 2.5 mg mL−1, and left to equilibrate for 24 h before 
measurement to ensure nanoassembly formation. To perform FRET 
experiments, the samples were excited at a wavelength of 500 nm and 
the emission profile was collected from 545 to 800 nm using a Tecan 
infinite M200 Pro Microplate reader. The emission fluorescence of 
Cy5 (at 647 nm) was divided by the emission fluorescence of the Cy3 
(561 nm) to obtain FRET ratios.
Nanosight Measurements: Nanoparticle tracking analysis was 
performed on a NS300 apparatus equipped with a complementary 
metal-oxide-semiconductor (CMOS) camera mounted on an optical 
microscope to track scattered light by particles illuminated a focused 
(80 µm) beam generated by a single mode laser diode (488 nm). This 
technique combines a conventional optical microscope with a laser 
light source to illuminate nanoscale particles within the sample (mL) 
introduced to the viewing unit with a disposable syringe. Laser light 
illuminates particles in suspension and a video camera captures the 
scattered light produced. Particle diffusion was determined by tracking 
individual particle positional changes in two dimensions, from which 
hydrodynamic diameter could then be determined for each particle, 
thereby providing direct measurement on size and particle counts. 
Particles were tracked using the built-in software for 60 s at 30 fps at 
25 °C. The particle sizes and concentrations were evaluated employing 
the Nanoparticle Tracking Analysis (NTA) software, data are represented 
as mean hydrodynamic diameter and particles per mL.
STORM: To perform direct STORM imaging, star-shaped poly(L-
glutamates) were immobilized by adsorption onto the surface 
of a flow chamber assembled from a glass slide and a coverslip 
(24 mm × 24 mm, thickness 0.15 mm) separated by double-sided tape. 
After being incubated for 10–15 min, unbound structures were removed 
by washing the chamber twice with STORM buffer. STORM buffer 
contains phosphate buffer saline (PBS), an oxygen scavenging system 
(0.5 mg mL−1 glucose oxidase, 40 µg mL−1 catalase), 5% (w/v) glucose, 
and 100 × 10−3 M cysteamine.
STORM images were acquired using a Nikon N-STORM system 
configured for total internal reflection fluorescence imaging. 
Compound 2d was imaged by means of a 647 nm laser (160 mW) and 
compound 2c was imaged by means of a 488 nm laser (80 mW). No 
activation of UV light was employed. Fluorescence was collected by 
means of a Nikon 100×, 1.49 numerical aperture (NA) oil-immersion 
objective and passed through a quad-bandpass dichroic filter (97335 
Nikon). Images were acquired onto a 256 × 256 pixel region (pixel size 
0.16 µm) of a Hamamatsu ORCA- Flash 4.0 camera at 10 ms integration 
time. STORM images were analyzed with the STORM module of the NIS 
element Nikon software. The NIS element Nikon software generates a 
list of localizations by Gaussian fitting of blinking dyes in the acquired 
movie of conventional microscopic images. This analysis takes around 
2 min per image, and can be run in a batch mode. To avoid overcounting, 
blinking detected in consecutive frames are counted as single by the 
software.
NMR Experiments: NMR spectra were recorded at 27 °C (300 K) on 
an Avance III 500 MHz Bruker spectrometer equipped with a 5 mm 
TBI broadband probe or a 300 Ultrashield from Bruker (Billerica, MA, 
USA). Data were processed with the software Mestrenova (Bruker 
GmbH, Karlsruhe, Germany). Samples were prepared at the desired 
concentration in D2O.
Diffusion Experiments (500 MHz): Pulsed-field-gradient NMR 
spectroscopy was used to measure translational diffusion by fitting the 
integrals or intensities of the NMR signals to the Stejskal–Tanner[41] 
equation: I = I0exp[−Dγ2g2δ2(∆ − δδ3)] where I is the observed intensity, 
I0 the reference intensity (unattenuated signal intensity), D the diffusion 
coefficient, γ the gyromagnetic ratio of the observed nucleus, g the 
gradient strength, δ the length of the gradient, and ∆ the diffusion 
time. 2D diffusion-ordered NMR spectroscopy was performed with a 
stimulated echo sequence using bipolar gradient pulses. The lengths 
of delays were held constant at ∆ = 10 ms, and 32 spectra of 64 scans 
Adv. Mater. 2017, 1702888
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each were acquired with the strength of the diffusion gradient varying 
between 5% and 95%. The lengths of the diffusion gradient and the 
stimulated echo were optimized for each sample. Typical values were 
δ = 1.5 ms for the analysis of nonaggregated species (0.1 mg mL−1) and 
5 ms to study the nanoassemblies.
NOE Experiments (500 MHz): 2D NOE experiments (NOESY) where 
recorded with a mixing time of 100 ms with 128 scans.
Cell-Culture Protocols: SHSY5Y cells from ATCC were cultured in 
Dulbecco’s modified Eagle medium (DMEM) media supplemented with 
fetal bovine serum. Cells were maintained at 37 °C in an atmosphere 
of 5% carbon dioxide and 95% air. Medium was replaced every 2–3 d 
and underwent passage once weekly when 80% of cell confluence was 
reached.
MTS Assay for Cell Viability: Cells were seeded in sterile 96-well 
microtiter plates at a cell density of 35 000 cells cm−2 for SHSY5Y. Plates 
were incubated for 24 h and compounds (0.2 µm filter sterilized) were 
then added to give a final concentration of 0–3 mg mL−1. After 72 h of 
incubation, (3-(4,5-dimethylthiazol-2-yl)-5- (3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium) (MTS)/phenazine methosulfate (PMS) 
(20:1) (10 µL of manufacturer solution) was added to each well, and the 
cells were incubated for a further 2 h. Optical density of each well was 
measured at 490 nm spectrophotometrically using Victor2Wallac plate 
reader. The absorbance values were represented as the percentage of 
cell viability taken as 100% cell viability of untreated control cells.
Cellular Uptake by Flow Cytometry of Oregon Green-Labeled Polymers 
in SHSY5Y Cells: SHSY5Y cells were seeded in 6-well plates at a density 
of 35 000 cells cm−2 (1 mL cell suspension per well) and allowed to 
adhere for 24 h. In binding experiments conducted at 4 °C, cells were 
preincubated at this temperature for 30 min prior to starting the 
experiment. For both experiments, 4 and 37 °C, the cathepsin B inhibitor 
CA-074 (0.4 µL from a solution of 5 × 10−6 M to reach a final concentration 
of 2 × 10−6 M) was added 30 min before the addition of the conjugate. 
Then, 10 µL of Oregon Green (OG)-labeled polymer (0.01 mg OG per 
mL) was added at different time points from 0 to 300 min while cells 
were incubated either at 37 or 4 °C for each experiment. Finally, cells 
were placed on ice to inhibit energy dependent mechanisms and washed 
twice with cold PBS–BSA 0.1%. (PBS supplemented with bovine serum 
albumin (BSA)). Then, cells were resuspended in 0.5 mL of cold PBS 
using a cell scraper. Finally, the cell pellet was placed in flow cytometer 
tubes. Cell-associated fluorescence (CAF) was then analyzed using 
a Becton Dickinson fluorescence-activated cell sorting FACSCalibur 
cytometer (California, USA) equipped with an argon laser (488 nm) and 
emission filter for 550 nm. Data collection involved 10 000 counts per 
sample, and data were analyzed using CELLQuest version 3.3 software. 
Data are expressed by plotting the CAF, which is the result of the % of 
positive cells multiplied by the mean fluorescence (CAF = % positive 
cells × mean fluorescence/100). Cells incubated without polymer were 
used to account for the background fluorescence.
Statistical Analysis: Data from the experiments were analyzed using 
one-way analysis of variance (ANOVA). In all cases, differences were 
considered to be significant when ***p < 0.001; **p < 0.01; *p < 0.05; 
ns: nonsignificant.
Confocal Fluorescence Microscopy—Live-Cell Imaging: For live-cell 
imaging, SHSY5Y cells were seeded at a density of 35 000 cells cm−2, on 
glass bottom culture dishes (1 cm2 Petri plate) and allowed to seed for 24 h 
at 37 °C. The experiment was performed following a pulse–chase mode at 
37 °C. First, the cathepsin B inhibitor CA-074 (0.4 µL from a solution of 
5 × 10−6 M to reach a final concentration of 2 × 10−6 M) was added 30 min 
prior the addition of the St–PGA–OG. Then, 10 µL of OG-labeled polymer 
(0.01 mg OG per mL) was added and the cells were incubated for 2 h at 
37 °C (pulse). The medium was removed and cells were washed twice 
with PBS. 1 mL of medium containing 2 × 10−6 M of the CA-074 inhibitor 
was then added, and cells were incubated for 4 h at 37 °C (chase). 
30 min before washing the cells with PBS–BSA 0.1%, the nuclear marker 
Hoechst (1 µL from a solution of 5 × 10−6 M) and the lysosomal marker 
LysoTracker Red (0.75 µL from a solution of 100 × 10−6 M) were added 
and incubated for 20 min in order to identify possible co-localizations 
and therefore establish an endocytic pathway. Finally, cells were washed 
with PBS–BSA 0.1%. Then, the glass was removed and placed on the 
microscope chamber with fresh media containing 2 × 10−6 M of CA-074 
inhibitor. Samples were analyzed under the microscope. Images were 
captured with an inverted DM IRE2 microscope equipped with a 
λ-blue 60× oil immersion objective and handled with a TCS SP2 system, 
equipped with an acoustic optical beam splitter. Excitation was performed 
with an argon laser (OG 496 nm), HeNe laser (LysoTracker Red 594 nm), 
and blue diode (Hoechst 405 nm). Images were captured at an 8-bit 
gray scale and processed with Leica Confocal Software (LCS) (version 
2.5.1347a, Leica Germany) containing multicolor, macro-, and 3D 
components. Control cells that followed the same incubation time were 
also analyzed to establish the autofluorescence, as well as cells treated 
only with Hoechst or LysoTracker Red.
Biodistribution Experiment and Fluorescence Quantification: 
Biodistribution experiments were carried out using female athymic nude 
mice of five to seven weeks from Envigo. Animals were housed on a 
12 h light and 12 h dark cycle. Water and food was provided ad libitum 
during the whole experiments in all cases, and general aspect, behavior, 
and body weight were evaluated daily to ensure animal wellness. All 
animal protocols were approved by the Institutional Animal Care and 
Use Committee at the Centro de Investigación Príncipe Felipe (Valencia, 
Spain). For the pharmacokinetics and biodistribution study, 30 mice were 
used (five mice at each time point, 25 ± 4.5 g of body weight). The labeled 
polymer was administered intravenously through the tail vein at a dose of 
4.15 mg kg−1 Cy5.5 eq. (5.41 mg mL−1 polymer) in serum saline. Mice were 
euthanized at 0, 4, 8, 24, 48, and 72 h postadministration. Blood, major 
organs (heart, lungs, spleen, liver, kidneys, and brain), and small organs 
(ovaries, adrenal glands, axillary and cervical lymph nodes) were harvested 
after flushing with 10 mL PBS. Then, organs were weighted and stored 
at −80 °C for subsequent homogenation and fluorescence quantification. 
Blood samples were centrifuged immediately after extraction (10 min, 
4000 rpm, 4 °C) and plasma (supernatant) and pellet were stored 
separately at −80 °C. For fluorescence quantification, major organs and 
fallopian tube were homogenized in Dulbecco’s phosphate buffered-saline 
(DPBS) pH = 7.4 at a specific concentration by means of Ultraturrax 
device and the rest of the small organs were homogenized manually with 
a potter glass (see Table S5 in the Supporting Information). Suspensions 
obtained were centrifuged (4000 rpm, 1 h, 4 °C) and supernatants were 
collected for fluorescence measurement. Supernatants of organs collected 
and plasma were measured (100 µL) per triplicate in 96 well-plates using 
Victor2Wallace by fluorescence (595 nm excitation and 680 nm emission). 
To relate the fluorescence with the concentration of conjugate present in 
the organ, a calibration curve was previously performed.
Statistical Analysis: Data from the experiments were analyzed using 
one-way ANOVA and Bonferroni posthoc for pairwise comparison. In all 
cases, differences were considered to be significant when ***p < 0.001; 
**p < 0.01; *p < 0.05; ns: nonsignificant. ***p < 0.001 5b versus star, 
###p < 0.001 5b versus PGA, t t tp < 0.001 5b versus Cy5.5.
Pharmacokinetics: The data analysis was performed by nonlinear 
regression using the SOLVER function of the spreadsheet program 
Microsoft Excel as has been described by Martin et al.[42] (the 
pharmacokinetic parameters were A, B, ALPHA, and BETA). From these 
parameters, several derived pharmacokinetic parameters were computed: 
AUC (A/ALPHA + B/BETA), CL (D/AUC), Vss, Cmax (A + B), and apparent 
terminal half-life. As plasma concentrations often span a wide range, it is 
useful to employ a weighting procedure for the raw data that allows one to 
fit low concentrations and high concentrations simultaneously. Weighting 
by the deviation standard of the concentration was used: Weighting: 1/Y2.
Histology: Key organs for the determination of the absence of toxicity 
after 5b administration to mice were extracted from euthanized animals 
at 24 and 72 h biodistribution time points. After being washed with PBS, 
kidneys, livers, and spleen were fixed in paraformaldehyde (PFA) for 24 h. 
Then, the excess of PFA was removed by washing with PBS under strong 
agitation (200 rpm) for 20 min, five times. Finally, samples were stored 
in a solution of PBS with 0.05% of sodium azide. In order to include the 
sample in paraffin, a previous dehydration of the sample through 2 min 
incubation in increased degree of alcohol solutions (30%, 50%, 70%, 
96%, and 99.9%) was performed, followed by two xylol washes of 1 min 
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to finally include the sample in paraffin. Then, the paraffin block was cut 
in 5 µm slide and set up in SuperFrost plus glass slide to hematoxylin–
eosin staining. For hematoxylin–eosin staining, previous tissue slides 
were deparaffinized with xylene and then rehydrated with a decreasing 
battery of ethanol solutions (99.9%, 96%, 70%) and water (5 min) 
followed by Dako hematoxylin staining for 2.5 min. Tissue samples were 
then washed with deionized water (1.5 min bath), blueing buffer (1 min), 
and water (1.5 min). Then, tissue slides were incubated 2 min in lithium 
carbonate and HCl 0.25% in ethanol 70% in order remove the excess of 
hematoxylin staining. Following that, tissue slides were incubated with 
Dako eosin for 2 min. Finally, dehydration was performed by washing 
with 96% ethanol (30 s) and 99.9% ethanol (2.5 min). The slide was 
then mounted with Eukitt.
Supporting Information
Supporting Information is available from the Wiley Online Library or 
from the author.
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